Physician profile
Robert R Roeser
NPI 1689670960
$1,179.96
in general payments reported to CMS, 2019-2025
14 companies · $175 in 2025
The $175 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $141 · 2021: $337 · 2022: $153 · 2023: $78.87 · 2024: $75.94 · 2025: $175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $330.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $329.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $236.57 | 2020-2022 | |
| Abbvie INC. | $216.26 | 2019-2024 | Ubrelvy |
| Sanofi-Aventis U.S. LLC | $162.95 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $141.52 | 2021-2025 | Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $92.23 | 2019-2025 | |
| Novo Nordisk INC | $85.79 | 2019-2024 | Ozempic |
| Abbott Laboratories | $76.81 | 2022-2023 | Cardiomems |
| Bayer Healthcare Pharmaceuticals INC. | $66.66 | 2022-2025 | |
| Eisai INC. | $27.70 | 2024 | |
| Amgen INC. | $17.71 | 2019 | |
| Amarin Pharma, INC. | $15.36 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.71 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $14.29 | 2020 | |
| Allergan, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Roeser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.